{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:57:39Z","timestamp":1785513459295,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Germline\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                      pathogenic and likely pathogenic variants (PVs) significantly increase the risk of breast cancer and ovarian cancer, forming the basis for hereditary breast and ovarian cancer syndrome. Current guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with PVs. This study aimed to evaluate the rate of uptake of RRSO among women with breast cancer who carry germline BRCA PVs. This retrospective study collected data from women with breast cancer who were identified to have germline BRCA PVs between 2020 and 2024 at Siriraj Hospital, Bangkok, Thailand. Baseline characteristics, including age, BMI, underlying diseases, menopausal status, recurrent or metastatic breast cancer,\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                      PVs were recorded. The uptake rate and associated factors of RRSO among these women were analyzed. In addition, the time to surgery and pathological outcomes were evaluated in the RRSO group. One hundred and thirty-eight women were included in the final analysis. Among them, 81 (58.7%) underwent RRSO. Ovarian cancer was detected in six (7.4%) women who underwent RRSO. Factors associated with undergoing RRSO including age greater than or equal to 45 years and the absence of distant metastasis. The median interval between genetic testing and RRSO was 8 months. In the surveillance group, the median follow-up time was 39 months, and no cases of cancer were detected. The RRSO uptake rate among breast cancer patients with germline\n                      <jats:italic toggle=\"yes\">BRCA<\/jats:italic>\n                      PVs was 58.7%. Efforts to improve this rate should focus on understanding reasons for refusal and offering alternative prevention strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cej.0000000000001005","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:00:13Z","timestamp":1769007613000},"page":"457-464","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants"],"prefix":"10.1097","volume":"35","author":[{"given":"Supapan","family":"Pradutchon","sequence":"first","affiliation":[{"name":"Obstetrics and Gynecology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manop","family":"Pithukpakorn","sequence":"additional","affiliation":[{"name":"Medicine"},{"name":"Siriraj Genomics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitcha","family":"Poonyakanok","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"R1-20260731","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/ijms21031128","article-title":"Genetic predisposition to breast and ovarian cancers: how many and which genes to test?","volume":"21","author":"Angeli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R2-20260731","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-024-07283-0","article-title":"Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1\/2 variants evaluated at a large urban comprehensive cancer center.","volume":"206","author":"Assad","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"R3-20260731","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1467-842X.2001.tb00294.x","article-title":"How can I deal with missing data in my study?","volume":"25","author":"Bennett","year":"2001","journal-title":"Aust N Z J Public Health"},{"key":"R4-20260731","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance.","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-20260731","doi-asserted-by":"crossref","first-page":"pkaa029","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis.","volume":"4","author":"Chen","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"R6-20260731","doi-asserted-by":"crossref","first-page":"573","DOI":"10.31557\/APJCP.2022.23.2.573","article-title":"Perspectives of gynecologic oncologists on minimally invasive surgery during COVID-19 pandemic: a Turkish society of Minimally Invasive Gynecologic Oncology (MIJOD) Survey.","volume":"23","author":"Dogan","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"R7-20260731","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.","volume":"7","author":"Domchek","year":"2006","journal-title":"Lancet Oncol"},{"key":"R8-20260731","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-010-0799-x","article-title":"Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1\/2 mutation carriers.","volume":"124","author":"Domchek","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R9-20260731","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"R10-20260731","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bpobgyn.2020.01.006","article-title":"Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.","volume":"65","author":"Gaba","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R11-20260731","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R12-20260731","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41525-024-00400-4","article-title":"Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand.","volume":"9","author":"Kansuttiviwat","year":"2024","journal-title":"NPJ Genom Med"},{"key":"R13-20260731","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"R14-20260731","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00432-015-2051-x","article-title":"Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.","volume":"142","author":"Kim","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"R15-20260731","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/jog.13845","article-title":"Sectioning and extensively examining the fimbriated end (SEE-FIM) of the fallopian tube in routine practices, is it worth the effort?","volume":"45","author":"Laokulrath","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"R16-20260731","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2017.28.e3","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"R17-20260731","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-021-06152-4","article-title":"Thai patients who fulfilled NCCN criteria for breast\/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.","volume":"188","author":"Lertwilaiwittaya","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"R18-20260731","doi-asserted-by":"crossref","first-page":"1257668","DOI":"10.3389\/fpubh.2023.1257668","article-title":"A cost-utility analysis of BRCA1 and BRCA2 testing in high-risk breast cancer patients and family members in Thailand: a cost-effective policy in resource-limited settings.","volume":"11","author":"Lertwilaiwittaya","year":"2023","journal-title":"Front Public Health"},{"key":"R19-20260731","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3349\/ymj.2021.62.12.1090","article-title":"Uptake rate of risk-reducing salpingo-oophorectomy and surgical outcomes of female germline BRCA1\/2 mutation carriers: a retrospective cohort study.","volume":"62","author":"Lim","year":"2021","journal-title":"Yonsei Med J"},{"key":"R20-20260731","first-page":"e2022051","article-title":"A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.","volume":"93","author":"Loizzi","year":"2022","journal-title":"Acta Biomed"},{"key":"R21-20260731","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2019.04.055","article-title":"WISP: a prospective, multi-center trial of salpingectomy with delayed oophorectomy versus risk reducing salpingo-oophorectomy in women at increased risk for hereditary ovarian cancer.","volume":"154","author":"Lu","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R22-20260731","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review.","volume":"13","author":"Lukasiewicz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R23-20260731","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer.","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"R24-20260731","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis.","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"R25-20260731","doi-asserted-by":"crossref","first-page":"e2300417","DOI":"10.1200\/GO.23.00417","article-title":"Uptake of risk-reducing measures, cascade testing, and related challenges among carriers of breast cancer-associated germline pathogenic variants in Mexico.","volume":"10","author":"Mesa-Chavez","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"R27-20260731","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"R28-20260731","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2021.08.021","article-title":"Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).","volume":"163","author":"Saccardi","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R29-20260731","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jnci\/djac004","article-title":"Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits.","volume":"114","author":"Schrijver","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"R30-20260731","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"R31-20260731","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","article-title":"Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk \u2013 combined results from two screening trials.","volume":"23","author":"Skates","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R32-20260731","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial.","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol"},{"key":"R33-20260731","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","article-title":"TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"R34-20260731","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R35-20260731","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CEJ.0000000000001005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:02:53Z","timestamp":1785510173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CEJ.0000000000001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000001005","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-10-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}